دورية أكاديمية
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
| العنوان: | Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors |
|---|---|
| المؤلفون: | Occhipinti, Mario, Brambilla, Marta, Galli, Giulia, Manglaviti, Sara, Giammaruco, Maristella, Prelaj, Arsela, Ferrara, Roberto, De Toma, Alessandro, Proto, Claudia, Beninato, Teresa, Zattarin, Emma, Lo Russo, Giuseppe, Gelibter, Alain Jonathan, Simmaco, Maurizio, Preissner, Robert, Garassino, Marina Chiara, De Braud, Filippo, Marchetti, Paolo |
| المساهمون: | Occhipinti, Mario, Brambilla, Marta, Galli, Giulia, Manglaviti, Sara, Giammaruco, Maristella, Prelaj, Arsela, Ferrara, Roberto, De Toma, Alessandro, Proto, Claudia, Beninato, Teresa, Zattarin, Emma, Lo Russo, Giuseppe, Gelibter, Alain Jonathan, Simmaco, Maurizio, Preissner, Robert, Garassino, Marina Chiara, De Braud, Filippo, Marchetti, Paolo |
| سنة النشر: | 2021 |
| المجموعة: | RE.PUBLIC@POLIMI - Research Publications at Politecnico di Milano |
| مصطلحات موضوعية: | Drug-PIN®, EGFR, drug–drug interactions (DDI), non-small-cell lung cancer (NSCLC), tyrosine-kinase inhibitors (EGFR-TKIs) |
| الوصف: | (1) Background. The onset of a drug-drug interaction (DDI) may affect treatment efficacy and toxicity of advanced non-small-cell lung cancer (aNSCLC) patients during epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) use. Here we present the use of Drug-PIN(R) (Personalized Interactions Network) software to detect DDIs in aNSCLC patients undergoing EGFR-TKIs. (2) Methods. We enrolled patients with Stage IV aNSCLC already treated with or candidates to receive EGFR-TKIs, in any line; ECOG PS 0-2; taking at least one concomitant drug. Cancer treatments, concomitant drugs, and clinical and laboratory data were collected and inserted in Drug-PIN(R). (3) Results. Ninety-two patients, median age of 68.5 years (range 43-89), were included. In total, 20 clinically relevant DDIs needing medical intervention in a total of 14 patients were identified; the 14 major DDIs were related to a high-grade interaction between TKIs and SSRIs, antipsychotics, antiepileptics, H2-receptor antagonist and calcium antagonists. A negative association between statin intake and PFS was identified (p = 0.02; HR 0.281, 95% CI 0.096-0.825). (4) Conclusions. This is the first retrospective study assessing the prevalence of DDIs, the clinical need for medical intervention and the impact of concomitant drugs on EGFR-TKIs survival in aNSCLC. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/34069851; info:eu-repo/semantics/altIdentifier/wos/WOS:000654188100001; volume:11; issue:5; firstpage:424; lastpage:427; numberofpages:4; journal:JOURNAL OF PERSONALIZED MEDICINE; http://hdl.handle.net/11311/1220888Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85107407664 |
| DOI: | 10.3390/jpm11050424 |
| الإتاحة: | https://doi.org/10.3390/jpm11050424Test http://hdl.handle.net/11311/1220888Test |
| رقم الانضمام: | edsbas.62D3EFF8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/jpm11050424 |
|---|